We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A053: Effect of different angiotensin II antagonists on fibrinolysis in hypertensive post-menopausal women.
- Authors
Fogari*, R.; Zoppi*, A.; Corradi, L.; Mugellini, A.; Pasotti, C.; Poletti, L.; Pesce, R.M.; Preti, P.
- Abstract
Aim of this study was to compare the effect of different Angio II Antagonists on plasma PAI-1 in hypertensive post-menopausal women, a population with impaired fibrinolysis.We studied 97 hypertensive (DBP > 90 and < 105 mmHg) post-menopausal women, aged 51 to 60 years not taking any hormone replacement therapy; diabetic, obese and smoker patients were excluded. After a 4 week placebo period they were randomly allocated to be administered Losartan 50 to 100 mg (n = 22). Valsartan 80 to 160 mg (n = 24), Irbesartan 150 to 300 mg (n = 25) and Candesartan 8 to 16 mg (n = 26) for 12 weeks. For the first 4 weeks the lowest dose of each drug was used then there was a titration. At the end of the placebo period and of the treatment period blood pressure was measured and blood samples were taken (in the morning between 00700 and 00900 h) to evaluate plasma PAI-1.The main results (mean changes versus placebo), are as follows: (See Table)In conclusion in hypertensive post-menopausal women Candesartan induces a significant increase in plasma PAI-1 not evident with other Angio II antagonists and independent of BP reduction. This could be due to its stronger and insormountable binding to AT-1 receptors and to the consequent greater reactive activation of the Renin-Angiotensin system with increased production of Ag IV, the physiological agonist for endothelial PAI-1 synthesis.Am J Hypertens (2000) 13, 130A-130A; doi:S0895-7061(00)00586-0
- Publication
American Journal of Hypertension, 2000, Vol 13, p130A
- ISSN
0895-7061
- Publication type
Article
- DOI
10.1016/S0895-7061(00)00586-0